PRESS RELEASE

FRI, SEP 18, 2020 08:30 CET

RLS Global presents data about ChloraSolv and its rapid response and high efficacy on biofilm

At the EWMA (European Wound Management Association) Conference in November, RLS will present data where our technology has been evaluated in an ex-vivo wound model with very exciting results on biofilm. The evaluation was carried out together with RISE, Research Institute of Sweden.

Biofilm is challenging in Wound Management. Staphylococcus aureus and Pseudomonas aeruginosa are two common bacteria that form biofilms in chronic wounds. A biofilm is formed by a high number of bacteria that protect themselves through a secretion of a viscous barrier. One consequence of biofilm formation is that the individual’s ability to kill bacteria through their immune system is hindered. Another consequence is that the bacteria is protected from antibiotics and several antiseptics.

The purpose of the study was to investigate the effect of ChloraSolv on these two bacteria. The results show that ChloraSolv has a rapid effect on both bacteria. In Staphylococcus aureus biofilm, 33% of the bacteria were killed in 30 seconds and more than 81% in five minutes. The effect on Pseudomonas aeruginosa is more immediate and kills more than 95% after 30 seconds. After five minutes, 97% of the bacteria are gone from the wound model.

To follow up on these results, RLS initiated a research program together with scientists from Lund University. The purpose is to investigate ChloraSolv’s effect on new biofilm models. The aim was to investigate biofilm reduction in the treatment of chronic wounds, but also in new clinical areas such as dermatology and burns. The results so far are very promising and will be published in a scientific journal.

‘RLS’s long-term strategy is to broaden the company’s product portfolio with products in new clinical areas. It is gratifying that we have now produced new, promising data that support our product development strategy, says Karin Fischer, CEO RLS Global. Karin continues, RLS has a unique platform with its buffered hypochlorite solution that has great potential for areas where biofilm is a problem.

Contact information

Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702 48 46 51

Mats Ahlenius, CTO
E-mail: mats.ahlenius@rlsglobal.se
Telephone: +46 707 41 03 39

Publication

RLS Global AB (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation. The information was submitted for publication through the agency of the above contact person, at 08.30 CET on September 18th, 20

Press Release